Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040680 | 0.88 | CCR2 (0.48) | HSD17B10KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3050672 | 0.87 | CCR2 (0.53) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3062074 | 0.85 | CCR2 (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3049934 | 0.84 | L3MBTL3 (0.49) | KMT2AMEN1ALDH1A1SMN1; SMN2METAP2 | |
| SCHEMBL3054853 | 0.81 | POLB (0.52) | KMT2AMEN1KDM4ECCR2POLB | |
| SCHEMBL3050369 | 0.80 | POLB (0.51) | KMT2AMEN1KDM4ECCR2POLB | |
| SCHEMBL3059108 | 0.80 | HSD17B10 (0.45) | HSD17B10ALDH1A1KDM4EGLAGAA | |
| SCHEMBL3054191 | 0.80 | CACNA1B (0.62) | KMT2AMEN1POLBCACNA1HCACNA1B | |
| SCHEMBL3053914 | 0.80 | TAOK1 (0.47) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13835112 | 0.79 | POLB (0.53) | KMT2AMEN1KDM4ECCR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | claimed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | claimed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | claimed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | claimed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | claimed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | HSD17B10 4394/4885KMT2A 2478/4885MEN1 2640/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | HSD17B10 4396/4885KMT2A 2406/4885MEN1 2895/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | HSD17B10 4300/4885KMT2A 2464/4885MEN1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.